cannabidiol hydroxyquinone: structure given in first source; an air oxidation product of cannabidiol; inhibits the hepatic microsomal drug-metabolizing enzymes of mice through the decrease of cytochrome P-450 content; RN given refers to (1R-trans)-isomer [MeSH]
HU-331 : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 11393311 |
| CHEMBL ID | 4635276 |
| SCHEMBL ID | 13609377 |
| CHEBI ID | 197014 |
| MeSH ID | M0199219 |
| Synonym |
|---|
| cbdhq |
| hu 331 |
| hu331 |
| cannabidiol hydroxyquinone |
| hu-331 |
| 137252-25-6 |
| 3-hydroxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylcyclohexa-2,5-diene-1,4-dione |
| CHEBI:197014 |
| 2,5-cyclohexadiene-1,4-dione, 3-hydroxy-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1r-trans)- |
| i7q196l4au , |
| unii-i7q196l4au |
| CCG-208732 |
| 2,5-cyclohexadiene-1,4-dione, 3-hydroxy-2-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl- |
| SCHEMBL13609377 |
| HMS3649F22 |
| AKOS030241459 |
| J-006987 |
| Q3825917 |
| DTXSID10929758 |
| vce 004 |
| SR-01000946715-1 |
| sr-01000946715 |
| cannabidiol hydroxyquinone (cbdhq) |
| bdbm50541572 |
| CHEMBL4635276 , |
| FS-7319 |
| cannabidiol hydroxyquinone (cbdhq) 100 microg/ml in acetonitrile |
| cannabidiol hydroxyquinone (cbdhq) 1000 microg/ml in acetonitrile |
| Class | Description |
|---|---|
| prenylquinone | A quinone substituted by a polyprenyl-derived side-chain. Prenylquinones occur in all living cells. Due to their amphiphilic character, they are mainly located in biological membranes where they function as electron and proton carriers in the photosynthetic and respiratory electron transport chains. Some prenylquinones also perform more specialised roles sucy as antioxidants and enzyme cofactors. Prenylquinones are classified according to ring structure: the main classes are menaquinones, phylloquinones, ubiquinones and plastoquinones. |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 | 10.5000 | AID1657599 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1657599 | Agonist activity at GAL4-tagged PPARgamma (unknown origin) transiently expressed in HEK293T cells co-transfected with GAL4-tagged luc incubated for 6 hrs by dual luciferase reporter gene assay | 2020 | Journal of natural products, 05-22, Volume: 83, Issue:5 ISSN: 1520-6025 | The Oxidation of Phytocannabinoids to Cannabinoquinoids. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (13.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (86.67%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| illimaquinone | monohydroxy-1,4-benzoquinones; prenylquinone | metabolite | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 5-demethoxyubiquinone-9 | prenylquinone | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cannabinol | dibenzopyran | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| cannabichromene | 1-benzopyran | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| cannabidiol | olefinic compound; phytocannabinoid; resorcinols | antimicrobial agent; plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| cannabigerol | phytocannabinoid; resorcinols | anti-inflammatory agent; antibacterial agent; antioxidant; appetite enhancer; cannabinoid receptor agonist; neuroprotective agent; plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| quinone | 1,4-benzoquinones | cofactor; human xenobiotic metabolite; mouse metabolite | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 | |
| malondialdehyde | dialdehyde | biomarker | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| etoposide | beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound | antineoplastic agent; DNA synthesis inhibitor | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| cannabielsoin | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |||
| cannabidiol | olefinic compound; phytocannabinoid; resorcinols | antimicrobial agent; plant metabolite | 1991 | 2022 | 12.6 | high | 0 | 0 | 1 | 6 | 5 | 2 | |
| nu 7441 | dibenzothiophenes | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| nk314 | 2019 | 2019 | 5.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |||
| phenanthrenes | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akinetic-Rigid Variant of Huntington Disease | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Angiogenesis, Pathologic | 0 | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Astrocytoma, Grade IV | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Benign Neoplasms | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Benign Neoplasms, Brain | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Body Weight | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Brain Neoplasms | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Experimental Neoplasms | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Glioblastoma | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Huntington Disease | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Neoplasms | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Article | Year |
|---|---|
| HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert opinion on investigational drugs, , Volume: 16, Issue:9 | 2007 |
| Article | Year |
|---|---|
| Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors. Molecular biology reports, , Volume: 46, Issue:4 | 2019 |